Drugs / GDC-229
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03091777 | Mar → Nov 2017 | bacterial vaginosis | Balmoral Medical company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GDC-229 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03091777 ↗ |
| Known as | Metronidazole | “A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel)...” NCT03091777 ↗ |